U.S. License Holder:
Teva Pharms. USA
Date of License:
September-14-2018
Last Update:
May-23-2023
FDA-Approved Indications
AJOVY (fremanezumab-vfrm) is a calcitonin gene-related peptide antagonist indicated for the preventive treatment of migraine in adults.
Inter Partes Review Proceedings
PTAB Portal
IPR Case No(s):
U.S. Patent No.
9,340,614 (Antagonist Antibodies Directed Against Calcitonin Gene-related Peptide and Methods Using Same)
Patent Owner
Teva Pharmaceuticals International GmbH
Petitioner(s)
Eli Lilly & Co.
§ 102 Challenge
N
§ 103 challenge
Y
Claim Types Challenged Under § 103
Composition of Matter Formulation
§ 103 Challenge Instituted
Y
Final Written Decision Issued
Y
Federal Circuit Appeal(s)
20-1747
IPR Status
Final Written Decision (All Challenged Claims Found Unpatentable); Federal Circuit Appeal Affirmed
U.S. Patent No.
9,266,951 (Antagonist Antibodies Directed Against Calcitonin Gene-related Peptide and Methods Using Same)
Patent Owner
Teva Pharmaceuticals International GmbH
Petitioner(s)
Eli Lilly & Co.
§ 102 Challenge
N
§ 103 challenge
Y
Claim Types Challenged Under § 103
Composition of Matter Formulation
§ 103 Challenge Instituted
Y
Final Written Decision Issued
Y
Federal Circuit Appeal(s)
20-1748
IPR Status
Final Written Decision (All Challenged Claims Found Unpatentable); Federal Circuit Appeal Affirmed
U.S. Patent No.
9,346,881 (Antagonist Antibodies Directed Against Calcitonin Gene-related Peptide and Methods Using Same)
Patent Owner
Teva Pharmaceuticals International GmbH
Petitioner(s)
Eli Lilly & Co.
§ 102 Challenge
N
§ 103 challenge
Y
Claim Types Challenged Under § 103
Composition of Matter Formulation
§ 103 Challenge Instituted
Y
Final Written Decision Issued
Y
Federal Circuit Appeal(s)
20-1749
IPR Status
Final Written Decision (All Challenged Claims Found Unpatentable); Federal Circuit Appeal Affirmed
U.S. Patent No.
9,890,210 (Antagonist Antibodies Directed Against Calcitonin Gene-related Peptide)
Patent Owner
Teva Pharmaceuticals International GmbH
Petitioner(s)
Eli Lilly & Co.
§ 102 Challenge
N
§ 103 challenge
Y
Claim Types Challenged Under § 103
Composition of Matter
§ 103 Challenge Instituted
Y
Final Written Decision Issued
Y
Federal Circuit Appeal(s)
20-1750
IPR Status
Final Written Decision (All Challenged Claims Found Unpatentable); Federal Circuit Appeal Affirmed
U.S. Patent No.
9,890,211 (Antagonist Antibodies Directed Against Calcitonin Gene-related Peptide)
Patent Owner
Teva Pharmaceuticals International GmbH
Petitioner(s)
Eli Lilly & Co.
§ 102 Challenge
N
§ 103 challenge
Y
Claim Types Challenged Under § 103
Composition of Matter
§ 103 Challenge Instituted
Y
Final Written Decision Issued
Y
Federal Circuit Appeal(s)
20-1751
IPR Status
Final Written Decision (All Challenged Claims Found Unpatentable); Federal Circuit Appeal Affirmed
U.S. Patent No.
8,597,649 (Antagonist Antibodies Directed Against Calcitonin Gene-related Peptide and Methods Using Same)
Patent Owner
Teva Pharmaceuticals International GmbH
Petitioner(s)
Eli Lilly & Co.
§ 102 Challenge
N
§ 103 challenge
Y
Claim Types Challenged Under § 103
Composition of Matter Formulation
§ 103 Challenge Instituted
Y
Final Written Decision Issued
Y
Federal Circuit Appeal(s)
20-1752
IPR Status
Final Written Decision (All Challenged Claims Found Unpatentable); Federal Circuit Appeal Affirmed
U.S. Patent No.
8,586,045 (Methods of Using Anti-CGRP Antagonist Antibodies)
Patent Owner
Teva Pharmaceuticals International GmbH
Petitioner(s)
Eli Lilly & Co.
§ 102 Challenge
N
§ 103 challenge
Y
Claim Types Challenged Under § 103
Method of Treatment
§ 103 Challenge Instituted
Y
Final Written Decision Issued
Y
Federal Circuit Appeal(s)
20-1876 (lead, consolidated with 20-1877 and 20-1878)
IPR Status
Final Written Decision (No Challenged Claims Found Unpatentable); Federal Circuit Appeal Affirmed
U.S. Patent No.
9,884,907 (Methods for Treating Headache Using Antagonist Antibodies Directed Against Calcitonin Gene-Related Peptide)
Patent Owner
Teva Pharmaceuticals International GmbH
Petitioner(s)
Eli Lilly & Co.
§ 102 Challenge
N
§ 103 challenge
Y
Claim Types Challenged Under § 103
Method of Treatment
§ 103 Challenge Instituted
Y
Final Written Decision Issued
Y
Federal Circuit Appeal(s)
20-1877 (consolidated with lead appeal 20-1876)
IPR Status
Final Written Decision (No Challenged Claims Found Unpatentable); Federal Circuit Appeal Affirmed
U.S. Patent No.
9,884,908 (Methods for Treating Headache Using Antagonist Antibodies Directed Against Calcitonin Gene-Related Peptide)
Patent Owner
Teva Pharmaceuticals International GmbH
Petitioner(s)
Eli Lilly & Co.
§ 102 Challenge
N
§ 103 challenge
Y
Claim Types Challenged Under § 103
Method of Treatment
§ 103 Challenge Instituted
Y
Final Written Decision Issued
Y
Federal Circuit Appeal(s)
20-1878 (consolidated with lead appeal 20-1876)
IPR Status
Final Written Decision (No Challenged Claims Found Unpatentable); Federal Circuit Appeal Affirmed
U.S. Patent No.
11,028,160 (Treating Refractory Migraine)
Patent Owner
Teva Pharmaceuticals International GmbH
Petitioner(s)
Eli Lilly & Co.
§ 102 Challenge
N
§ 103 challenge
Y
Claim Types Challenged Under § 103
Method of Treatment
§ 103 Challenge Instituted
Y
IPR Status
Instituted, Pending
U.S. Patent No.
11,028,161 (Treating Refractory Migraine)
Patent Owner
Teva Pharmaceuticals International GmbH
Petitioner(s)
Eli Lilly & Co.
§ 102 Challenge
N
§ 103 challenge
Y
Claim Types Challenged Under § 103
Method of Treatment
§ 103 Challenge Instituted
Y
IPR Status
Instituted, Pending
U.S. Patent No.
10,392,434 (Treating Refractory Migraine)
Patent Owner
Teva Pharmaceuticals International GmbH; Teva Pharmaceuticals USA, Inc.
Petitioner(s)
Eli Lilly & Co.
§ 102 Challenge
N
§ 103 challenge
Y
Claim Types Challenged Under § 103
Method of Treatment
§ 103 Challenge Instituted
Y
IPR Status
Instituted, Pending
U.S. Patent Litigations
PACER
Case No(s):
U.S. Patent Nos.
8,586,045 (Methods of Using Anti-CGRP Antagonist Antibodies) 8,597,649 (Antagonist Antibodies Directed Against Calcitonin Gene-Related Peptide and Methods Using Same) 9,266,951 (Antagonist Antibodies Directed Against Calcitonin Gene-Related Peptide and Methods Using Same) 9,340,614 (Antagonist Antibodies Directed Against Calcitonin Gene-Related Peptide and Methods Using Same) 9,346,881 (Antagonist Antibodies Directed Against Calcitonin Gene-Related Peptide and Methods Using Same)
Plaintiffs
Teva Pharmaceuticals International GmbH, Teva Pharmaceuticals USA, Inc.
Defendants
Eli Lilly & Co.
Status
Dismissed
BPCIA
N
U.S. Patent Nos.
9,884,907 (Methods for Treating Headache Using Antagonist Antibodies Directed Against Calcitonin Gene-Related Peptide) 9,884,908 (Methods for Treating Headache Using Antagonist Antibodies Directed Against Calcitonin Gene-Related Peptide) 9,890,210 (Antagonist Antibodies Directed Against Calcitonin Gene-Related Peptide) 9,890,211 (Antagonist Antibodies Directed Against Calcitonin Gene-Related Peptide)
Plaintiffs
Teva Pharmaceuticals International GmbH; Teva Pharmaceuticals USA, Inc.
Defendants
Eli Lilly & Co.
Status
Dismissed
BPCIA
N
U.S. Patent Nos.
8,586,045 (Methods of Using Anti-CGRP Antagonist Antibodies) 8,597,649 (Antagonist Antibodies Directed Against Calcitonin Gene-Related Peptide and Methods Using Same) 9,266,951 (Antagonist Antibodies Directed Against Calcitonin Gene-Related Peptide and Methods Using Same) 9,340,614 (Antagonist Antibodies Directed Against Calcitonin Gene-Related Peptide and Methods Using Same) 9,346,881 (Antagonist Antibodies Directed Against Calcitonin Gene-Related Peptide and Methods Using Same) 9,884,907 (Methods for Treating Headache Using Antagonist Antibodies Directed Against Calcitonin Gene-Related Peptide) 9,884,908 (Methods for Treating Headache Using Antagonist Antibodies Directed Against Calcitonin Gene-Related Peptide) 9,890,210 (Antagonist Antibodies Directed Against Calcitonin Gene-Related Peptide) 9,890,211 (Antagonist Antibodies Directed Against Calcitonin Gene-Related Peptide)
Plaintiffs
Teva Pharmaceuticals International GmbH, Teva Pharmaceuticals USA, Inc.
Defendants
Eli Lilly & Co.
Status
Jury Verdict (Claims Valid and Infringed)
BPCIA
N
U.S. Patent Nos.
11,028,160 (Treating Refractory Migraine) 11,028,161 (Treating Refractory Migraine)
Plaintiffs
Teva Pharmaceuticals International GmbH, Teva Pharmaceuticals USA, Inc.
Defendants
Eli Lilly & Co.
Status
Stayed Pending IPRs
BPCIA
N